Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

Amgen (AMGN) received a key approval from the European Commission for Tezspire as an add-on therapy for severe chronic ...

Today, in many places around the world, Halloween celebrations will take place.  The spooky holiday culminates with costumes, ...

Q3 2025 Earnings Call Transcript October 30, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.75 EPS, expectations were $-1.33. Operator: Thank you for standing by. My ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

Tarrytown, New York, Oct. 30, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates (ENTA), the nation’s preeminent otolaryngology, allergy, and audiology practice, proudly announces that ...

Losing your sense of smell could be an early warning sign that you're at risk of developing heart disease, according to a new ...